Brief: Galectin Therapeutics Announces Positive Top-Line Results From Phase 1B Trial Extension Of Belapectin In Combination With Keytruda®
09/07/2021 13:17
July 9 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS
FROM A
PHASE 1B CLINICAL TRIAL EXTENSION OF BELAPECTIN IN COMBINATION
WITH KEYTRUDA® IN ADVANCED METASTATIC MELANOMA AND HEAD AND NECK
CANCER
* GALECTIN THERAPEUTICS INC - COMBINATION OF BELAPECTIN AND
PEMBROLIZUMAB WAS WELL TOLERATED AND APPEARED SAFE
* GALECTIN THERAPEUTICS INC - THERE WERE NO GRADE 3 OR
ADVERSE
EVENTS
Source text for Eikon: ID:nGNX2TVtyC
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study